Directly from the USA: Infant Respiratory Tract Disease Risk Lower With Maternal RSV Vaccine
Pregnant women receiving the respiratory syncytial virus (RSV) prefusion F protein-based maternal vaccine (RSVPreF3-Mat) have offspring with lower risks for any and severe medically assessed RSV-associated lower respiratory tract disease; however, the vaccine may increase the risk for preterm birth, according to a study published in the March 14 issue of the New England Journal of Medicine.
Ilse Dieussaert, from GSK in Wavre, Belgium, and colleagues conducted a phase 3 trial involving pregnant women aged 18 to 49 years to examine the efficacy and safety of RSVPreF3-Mat. Women were randomly assigned to receive either RSVPreF3-Mat or placebo between 24 weeks 0 days and 34 weeks 0 days of gestation. Enrollment and vaccination were stopped early after the observation of a higher risk for preterm birth in the vaccine group.
Source: Advances and More licensed by HealthDay
